The COVID pandemic illustrated how urgently we need antiviral medications capable of treating coronavirus infections. To aid ...

Sushmi Dey ...

SARS-CoV-2 vaccines reduce the risk of COVID-19.1–3 However, some disease-modifying anti-rheumatic drugs (DMARDs), particularly glucocorticoids, methotrexate, mycophenolate mofetil and rituximab, may ...

A version of this article appears in print on , Section A, Page 24 of the New York edition with the headline: Immunotherapy Drug Spares Cancer Patients From Grisly Treatments.

A novel protein-based SARS-CoV2 vaccine strategy was safe and effective in preventing COVID-19 symptoms and related serious infections, according to research published in JAMA Network Open.

This method could further be expanded for drug repositioning for treating cardiovascular manifestations of COVID-19 by integrating SARS-CoV2 targets (covidome), CVD genes, and drug targets into the ...

Objectives We evaluated the effectiveness of COVID-19 vaccines and monoclonal antibodies (mAbs) against postacute sequelae of SARS-CoV-2 infection (PASC). Design and setting A retrospective cohort ...

ICMR has approved a new RT-qPCR kit developed by Chennai-based KRIYA Medical technologies that can detect the presence or absence of Influenza, SARS CoV2, and Respiratory Syncytial Virus (RSV).

The long-term side effects and potential development of resistance against existing drugs make it critical to develop new therapies against COVID-19. However, a crucial barrier to developing ...

Drug repurposing for COVID-19 is now an actively developing area of research. Unavailability of a proper set of interactions between SARS-CoV2 and human host proteins limits the set of possible ...